Suchergebnisse - "Lopinavir"

PubPharm (1.799)

51

COVID-19 "Rebound" associated with nirmatrelvir/ritonavir pre-hospital therapy

enthalten in: The Journal of infection | 2022

von Coulson, J. | Adams, A. | Gray, L. | +1

CommentIn: J Infect. 2022 Nov;85(5):e134-e136. - PMID 35995309

52

Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE) : A randomised, double-blind, 2 × 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19

enthalten in: PLoS medicine | 2022

von Lowe, D. | Brown, L. | Chowdhury, K. | +15

53

A systematic review and Bayesian network meta-analysis for comparative safety assessment of favipiravir interventions in hospitalized COVID-19 patients

enthalten in: Journal of infection in developing countries | 2022

von Yang, K. | Zeng, J. | Dai, W. | +2

54

Lopinavir/ritonavir, a new galenic oral formulation from commercial solid form, fine-tuned by nuclear magnetic resonance spectroscopy

enthalten in: European journal of hospital pharmacy : science and practice | 2022

von Desideri, I. | Martinelli, C. | Ciuti, S. | +2

55

In Silico Evaluation of Natural Flavonoids as a Potential Inhibitor of Coronavirus Disease

enthalten in: Molecules (Basel, Switzerland) | 2022

von Kashyap, P. | Thakur, M. | Singh, N. | +7

56

Can transcription factors in the intervertebral disc of lopinavir/ritonavir prevent degeneration in the nucleus pulposus by mediating the regulation of inflammation through signaling pathways?

enthalten in: European review for medical and pharmacological sciences | 2022

von Yilmaz, I. | Akalan, H. | Karaarslan, N. | +5

57

A Comparative Analysis of Physiologically Based Pharmacokinetic Models for Human Immunodeficiency Virus and Tuberculosis Infections

enthalten in: Antimicrobial agents and chemotherapy | 2022

von Mtshali, S. | Jacobs, B.

58

Long-acting HIV fusion inhibitor albuvirtide combined with ritonavir-boosted lopinavir for HIV-1-infected patients after failing the first-line antiretroviral therapy : 48-week randomized, controlled, phase 3 non-inferiority TALENT study

enthalten in: The Journal of infection | 2022

von Su, B. | Yao, C. | Zhao, Q. | +37

59

An open-label randomized, controlled trial of the effect of lopinavir and ritonavir, lopinavir and ritonavir plus interferon-β-1a, and hydroxychloroquine in hospitalized patients with COVID-19 : final results

enthalten in: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases | 2022

von Ader, F. | DisCoVeRy Study Group

60

Short-term Pregnancy Outcomes After Nirmatrelvir-Ritonavir Treatment for Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)

enthalten in: Obstetrics and gynecology | 2022

von Loza, A. | Farias, R. | Gavin, N. | +3